Many pharmaceutical manufacturers participate in U.S. government programs such as Medicaid, Medicare, Veterans Administration, 340B, and TRICARE, providing patients with access to discounted drugs. These programs have complex pricing and reporting requirements that are subject to federal and state compliance regulations. If these evolving regulations are not carefully followed, manufacturers may be vulnerable to monetary fines, civil and criminal penalties, CIAs, personal liability, and exclusion from future government programs participation. As the industry is challenged with pricing pressures from government agencies and politicians, scrutiny surrounding program integrity may likely increase.
Join Deloitte and Sidley Austin to learn how to evaluate your government pricing operations for your 2020 compliance workplan—including action items you may want to consider soon.